Will Green Cross challenge the domestic Lantus biosimilar market?

As Green Cross has made an attempt to avoid the patent of ‘Lantus,’ a Sanofi’s basal insulin, a background of the event has attracted interests.

The substance patent of Lantus will be expired on the 26^th of February next year, but Green Cross has not aimed for the date to develop its biosimilar.

According to the pharmaceutical industry on the 23^rd, Green Cross filed a defensive confirmation t...